UDALL PARKINSON?S DISEASE CENTER AT EMORY UNIVERSITY: CIRCUITRY TO THERAPY

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 埃默里大学最近资助的Morris K.Udall帕金森氏病卓越中心是一个高度合作的研究项目，电生理学家、药理学家和解剖学家共同从电路角度研究现有和新疗法对帕金森症的影响。该中心由四个项目和两个核心组成。项目1(Jaeger博士)研究了帕金森状态下改变的基底节输入对丘脑神经元的影响。项目2(Wichmann博士)是在帕金森灵长类动物身上进行的一系列实验，目的是比较苍白球和丘脑底核失活和刺激对丘脑的影响，这是治疗晚期帕金森病的常用方法，目的是确定与这些程序的抗帕金森效应相关的丘脑活动变化。项目3(米勒博士)是一系列翻译实验，考察了在不同的啮齿动物和灵长类动物模型中，口服活性TrkB受体激动剂作为对症或神经恢复性治疗帕金森病的使用。项目4(博士康恩，Vanderbilt)调查了新型亚型选择性毒鼠型乙酰胆碱受体拮抗剂和激活剂对基底节活动的影响，以及对啮齿动物模型帕金森病的影响。这些项目得到了一个行政核心(核心A，威奇曼博士，Pi；德隆博士，Co-I，皮尔逊博士，管理员)和一个解剖和行为核心(核心B，史密斯博士)的支持，该核心为所有中心项目提供免疫组织化学和电子显微镜服务，并在项目3下对接受MPTP治疗的猴子进行行为测试。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The recently funded Morris K. Udall Parkinson's Disease Center of Excellence at Emory University is a highly collaborative research program in which electrophysiologists, pharmacologists, and anatomists work together to study the effects of existing and new treatments for parkinsonism from a circuit perspective. The center consists of four projects and two cores. Project 1 (Dr. Jaeger) examines changes imposed by altered basal ganglia input onto thalamic neurons in the parkinsonian state. Project 2 (Dr. Wichmann) is a series of experiments in parkinsonian primates to compare the thalamic effects of pallidal and subthalamic nucleus inactivation and stimulation, as are commonly used to treat advanced parkinsonism in patients, with the goal of identifying changes in thalamic activity that are associated with the antiparkinsonian effects of these procedures. Project 3 (Dr. Miller) is a series of translational experiments that examine the use of orally active TrkB receptor agonists as symptomatic or neurorestorative treatment for Parkinson's disease in different rodent and primate models. Project 4 (Dr. Conn, Vanderbilt) investigates the effects of novel subtype-selective muscarinic acetylcholine receptor antagonists and activators on basal ganglia activity, and on parkinsonism in rodent models. The projects are supported by an administrative core (Core A, Dr. Wichmann, PI; Dr. DeLong, Co-I, Dr. Pearson, administrator), and by an anatomy and behavior core (Core B, Dr. Smith) which provides immunohistochemistry and electron microscopy services to all of the center projects, and conducts behavioral testing in MPTP-treated monkeys under project 3.